Nature of Business, Basis of Presentation and Going Concern Uncertainty - Additional Information (Detail) |
3 Months Ended | 12 Months Ended | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 23, 2018 |
Aug. 01, 2017
shares
|
Dec. 31, 2019
USD ($)
Product
|
Sep. 30, 2019
USD ($)
|
Jun. 30, 2019
USD ($)
|
Mar. 31, 2019
USD ($)
|
Dec. 31, 2018
USD ($)
|
Sep. 30, 2018
USD ($)
|
Jun. 30, 2018
USD ($)
|
Mar. 31, 2018
USD ($)
|
Dec. 31, 2019
USD ($)
Product
|
Dec. 31, 2018
USD ($)
|
Dec. 31, 2017
USD ($)
|
|
Nature Of Business And Basis Of Presentation [Line Items] | |||||||||||||
Reverse stock split ratio | 0.1 | ||||||||||||
Number of products approved for commercial sale | Product | 0 | 0 | |||||||||||
Revenue from product sales | $ 0 | ||||||||||||
Type of Revenue [Extensible List] | us-gaap:ProductMember | ||||||||||||
Net loss | $ (3,194,000) | $ (3,673,000) | $ (3,624,000) | $ (5,904,000) | $ (3,637,000) | $ (3,240,000) | $ (2,788,000) | $ (3,022,000) | $ (16,395,000) | $ (12,687,000) | $ (10,583,000) | ||
Accumulated deficit | (45,704,000) | $ (25,381,000) | (45,704,000) | (25,381,000) | |||||||||
Cash, cash equivalents and short term investments | 16,700,000 | 16,700,000 | |||||||||||
Working capital | $ 14,500,000 | 14,500,000 | |||||||||||
Net cash used in operations | $ 15,216,000 | $ 10,623,000 | $ 9,107,000 | ||||||||||
OncoGenex Pharmaceuticals, Inc [Member] | |||||||||||||
Nature Of Business And Basis Of Presentation [Line Items] | |||||||||||||
Reverse stock split ratio | 0.0909 | ||||||||||||
Conversion of each issued share of Achieve common stock , shares converted | shares | 821,011 |
X | ||||||||||
- Definition Conversion of shares common stock upon merger agreement. No definition available.
|
X | ||||||||||
- Definition Nature of business and basis of presentation. No definition available.
|
X | ||||||||||
- Definition Number of products approved for commercial sale . No definition available.
|
X | ||||||||||
- Definition The capital of a business which is used in its day-to-day trading operations, calculated as the current assets minus the current liabilities. No definition available.
|
X | ||||||||||
- Definition Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources. No definition available.
|
X | ||||||||||
- Details
|